Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer

Jpn J Thorac Cardiovasc Surg. 2001 Aug;49(8):489-96. doi: 10.1007/BF02919543.


Objectives: Neutral endopeptidase modulates the growth of lung cancer, while aminopeptidase N degrades the extracellular matrix and is involved in cell motility. We studied the metastasis mechanism to detect novel metastasis-associated molecules and to evaluate them for clinical application.

Methods: We studied the relationship between the expression of neutral endopeptidase and aminopeptidase N by quantitative reverse transcript-polymerase chain reaction analysis in 132 patients with non-small cell lung cancer undergoing radical surgery from 1991 to 1996.

Results: Patients with neutral endopeptidase-positive and aminopeptidase N-negative tumors were defined as group A, those with neutral endopeptidase-positive and aminopeptidase N-positive or neutral endopeptidase-negative and aminopeptidase N-negative tumors as group B, and those with neutral endopeptidase-negative and aminopeptidase N-positive tumors as group C. The 5-year survival of group A patients (92.9%) was significantly better than that of group B patients (64.7%) and much better than that of group C patients (38.2%) (P = 0.0011). Neutral endopeptidase and aminopeptidase N thus have statistically significant P in overall survival in Cox regression (P = 0.019).

Conclusion: Neutral endopeptidase and aminopeptidase N gene expressions are significant indicators of prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • CD13 Antigens / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Female
  • Gene Expression
  • Humans
  • Lung Neoplasms / mortality*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neprilysin / genetics*
  • Prognosis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Rate


  • CD13 Antigens
  • Neprilysin